- Home
- CAC vs EYPT Comparison
CAC vs EYPT Comparison
Compare CAC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAC | EYPT |
|---|---|---|
| Founded | 1875 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.1M | 1.3B |
| IPO Year | 1996 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CAC | EYPT |
|---|---|---|
| Price | $49.39 | $12.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $47.00 | $31.80 |
| AVG Volume (30 Days) | 75.9K | ★ 742.3K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 6.08 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $41,739,000.00 | $7,539,000.00 |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $6.05 | $3,115.57 |
| P/E Ratio | $38.07 | ★ N/A |
| Revenue Growth | ★ 16.96 | N/A |
| 52 Week Low | $35.00 | $5.46 |
| 52 Week High | $53.71 | $19.11 |
Technical Indicators
Market Signals| Indicator | CAC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 45.32 |
| Support Level | $47.25 | $12.66 |
| Resistance Level | $51.57 | $14.73 |
| Average True Range (ATR) | 1.13 | 0.74 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 81.88 | 43.60 |
Price Performance
Historical ComparisonAbout CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.